PHILADELPHIA (AFX) - GlaxoSmithKline and the New York-based Ludwig Institute for Cancer Research said GSK has licensed a substantial portfolio of tumor-specific antigens from LICR.
Financial details were not disclosed.
The licensing agreement follows a long-standing collaboration between both parties on GSK's investigational MAGE-A3 Antigen Specific Cancer Immunotherapeutic in Non-Small Cell Lung Cancer.
Under the terms of the agreement, GSK has licensed from LICR a significant number of cancer antigens expressed in a large variety of cancers, including NSCLC, melanoma, breast cancer, head and neck cancer, bladder cancer and liver cancer. newsdesk@afxnews.com vs/vs COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited